Seeking Alpha

Arena Pharmaceuticals Inc. (ARNA)

()

News & PR
Market Currents

Buzz
Twitter: ARNA

Business Intelligence
Transcripts
Events
Key Developments

Analysis - Latest Articles by most recent | most commented

Wall Street Breakfast: Must-Know News

Nov 10 • SA Editor Eli Hoffmann • 17 Comments
Options Trader: Wednesday Outlook, Fed Edition

Nov 4 • Philip Davis • Comment!
Amylin Takes Lead in Obesity Race

Nov 3 • Zacks.com • Comment!
Options Trader Testy Tuesday Outlook: Dow 9,650, Berkshire $60 Edition

Nov 3 • Philip Davis • 1 Comment
Don't Expect Amylin to Eat the Obesity Market's Lunch

Nov 2 • Ruthanne Williams Roussel • 11 Comments
Why Orexigen's Empatic News Is Good

Oct 2 • Ruthanne Williams Roussel • 6 Comments
Arena’s Lorcaserin Has Safety Edge

Sep 21 • Zacks.com • 4 Comments
Investing in the Obesity Drug Basket

Sep 21 • Michael Murphy • 14 Comments
BioMed News Bytes: Arena, Momenta, Vivus

Sep 20 • Mike Havrilla • Comment!
Friday Options Recap

Sep 18 • Frederic Ruffy • Comment!
Two Positive Notes for Arena Pharmaceuticals

Sep 18 • Ruthanne Williams Roussel • 11 Comments
BioMed News Bytes: Arena, ImmunoCellular, YM Bio

Sep 18 • Mike Havrilla • 3 Comments
Vivus: A One Trick Pony

Sep 11 • Ruthanne Williams Roussel • 11 Comments
Wednesday's Options Recap

Aug 26 • Frederic Ruffy • 2 Comments
Cramer Likes Orexigen: Should You?

Aug 18 • Ruthanne Williams Roussel • 4 Comments
Arena: Obesity Is a Large Market Opportunity

Aug 5 • Zacks.com • 1 Comment
Wall Street Breakfast: Must-Know News

Aug 4 • SA Editor Rachael Granby • 7 Comments
Arena's Edge in the Obesity Drug Race

Jul 26 • Beacon Asset Managers • 4 Comments
Five Small-Cap Weight Loss Trades

Jul 22 • Mike Havrilla • Comment!
Extreme FDA Trades: 20 Stocks Under 5 Bucks

Jul 21 • Mike Havrilla • 3 Comments
Vivus: Obesity Experimental Drug Has Promising Outlook

Jul 8 • Penn Bioinvestor • 8 Comments
Extreme FDA Trades: Another 18 Stocks Under 5 Bucks

Jul 5 • Mike Havrilla • 2 Comments
ADA Meeting 2009: Novel Diabetes Therapies Presented

Jun 24 • Michael Becker • 1 Comment
6 Healthcare Stocks to Watch

Jun 16 • M. E. Garza • 1 Comment
Arena Patients Keep Weight Off, Bodes Well for Partnership

Jun 10 • Ruthanne Williams Roussel • 2 Comments
NeuroSearch: Experimental Obesity Drug to Begin Phase 3 Trials

Jun 10 • Mike Havrilla • 1 Comment
FDA Calendar Updates: Keryx Biopharma Announces Phase 2 Results

Jun 9 • Mike Havrilla • 1 Comment
Bio Medical Stock Sector is Where the Action Is

Jun 9 • M. E. Garza • Comment!
A Biotech Triple Play: Dendreon, BioCryst and Arena

May 25 • Michael Murphy • 28 Comments
Arena's Prospects Will Be in the Eye of the Suitors

May 24 • Derek Lowe • 5 Comments
Arena Pharma Could Be on the Verge of Collapse

May 18 • Derek Lowe • 20 Comments
Pending Clinical Trial Results: Ten Extreme Trades

May 14 • Mike Havrilla • 8 Comments
Orexigen's Contrave: Generic Would Be No Cheaper

Apr 5 • Ruthanne Williams Roussel • 10 Comments
Q1 2009 Biotech Roundup: The Good, the Bad and the Ugly

Apr 2 • Mark Cifra • 5 Comments
FDA and Clinical Trial Updates: Weight Loss, Diabetes and More

Apr 2 • Mike Havrilla • 3 Comments
Arena, The Aftermath

Apr 2 • Ruthanne Williams Roussel • 11 Comments
Arena's Obesity Drug Not Likely to Make It

Mar 31 • Derek Lowe • 11 Comments
Arena's New Obesity Drug: Safe, But Not Too Efficacious

Mar 31 • Ruthanne Williams Roussel • 8 Comments
Monday's Options Recap

Mar 30 • Frederic Ruffy • 2 Comments
Monday Options Update: GM, VIX, XLF, BAC & ARNA

Mar 30 • Andrew Wilkinson • Comment!
Arena's Financing Deal with Azimuth Is a Healthy Move

Mar 25 • Mark Cifra • 10 Comments

Arena Pharmaceuticals Inc. (ARNA)

Analysis - Latest Articles by most recent | most commented

The Seeking Alpha 100

Fastest Climbers

Top Commenters

Top Instabloggers

Top StockTalkers